Table 1.
Characteristics of eligible studies on prognostic utility of the NLR in NSCLC patients receiving ICI.
| References | Study design | Year | Region | Sample | Male/female | Age (year), Median (range) | Squamous carcinoma/ adenocarcinoma/others | ICI | Calculation | Cut-off value | Follow-up period (months) | Outcome |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Bagley et al. (7) | Retrospective cohort | 2017 | USA | 175 | 80/95 | 68 (33–88) | 42/133 (Squamous/non-squamous) | Nivo | Baseline | 5 | NR | PFS, OS |
| Park et al. (31) | Retrospective cohort | 2017 | USA | 159 | 82/77 | 68 (41–91) | 109/39/11 | Nivo | Baseline | 5 | 11.5 (9.4–13.1) | PFS |
| Kataoka et al. (32) | Retrospective cohort | 2017 | Japan | 189 | 139/50 | 69 (38–88) | NR | Nivo | Baseline | 5 | 5.5 | PFS |
| Rogado et al. (33) | Retrospective cohort | 2017 | USA | 40 | 29/11 | 67 | NR | Nivo | Baseline | 5 | NR | PFS, OS |
| Patil et al. (34) | Retrospective cohort | 2017 | USA | 115 | 48/67 | 67 | NR | Nivo | Baseline | 2.8 | NR | PFS |
| Diem et al. (35) | Retrospective cohort | 2017 | Switzerland | 52 | 29/23 | 68 | 18/30/4 | Nivo | Baseline | 5 | 14.0 | PFS, OS |
| Shiroyama et al. (36) | Retrospective cohort | 2018 | Japan | 201 | 135/66 | 68 (27–87) | 41/160 (Squamous/non-squamous) | Nivo | Baseline | 4 | 12.4 | PFS |
| Zer et al. (37) | Retrospective cohort | 2018 | Canada | 88 | 43/45 | 64 (31–81) | 15/66/7 | PD-1/PD-L1 | Baseline | 4 | 5.3 (0.4–38.1) | PFS, OS |
| Mezquita et al. (38) | Retrospective cohort | 2018 | France | 466 | 301/165 | 62 (29–86) | 159/270/37 | PD-1/PD-L1 | Baseline | 3 | 12.0 (11.0–14.0) | PFS, OS |
| Fukui et al. (39) | Retrospective cohort | 2018 | Japan | 52 | 37/15 | 69 (46–83) | 16/33/3 | Nivo | Baseline | 5 | 10.9 (5.6–16.4) | OS |
| Maymani et al. (40) | Retrospective cohort | 2018 | USA | 74 | 36/38 | 68 | 12/62 (Squamous/non-squamous) | Nivo/Pembro/Durva | Baseline | 6 | 12.3 | OS |
| Petrova et al. (41) | Retrospective cohort | 2019 | Bulgaria | 119 | 74/45 | 62 | 51/68 (Squamous/non-squamous) | Pembro | Baseline | 5 | —— | PFS, OS |
| Liu et al. (42) | Retrospective cohort | 2019 | China | 44 | 33/11 | 60 (43–74) | 13/31/0 | Nivo | Baseline | 3.07 | 6.9 (0.6–28.5) | PFS, OS |
| Möller et al. (43) | Retrospective cohort | 2019 | Germany | 35 | 19/16 | 65 (24–85) | 7/23/5 | Nivo/Pembro | Baseline | 5.2 | 9.7 (1.0–26.0) | OS |
| Hasegawa et al. (44) | Retrospective cohort | 2019 | Japan | 51 | 40/11 | 70 (35–86) | 16/35 (Squamous/non-squamous carcinoma) | Pembro | Baseline | 4.56 | 9.5 (0.5–25.6) | PFS, OS |
| Dusselier et al. (45) | Retrospective cohort | 2019 | France | 59 | 44/15 | 60 (30–87) | 12/47 (Squamous/non-squamous carcinoma) | Nivo | Baseline | 5 | —— | OS |
| Russo et al. (46) | Retrospective cohort | 2020 | Italy | 187 | 137/50 | 67 (34–83) | 86/101 (Squamous/non-squamous carcinoma) | Nivo | Baseline | 5 | —— | OS |
NR, not reported; HR, hazard ratio; OS, overall survival; PFS, progression-free survival; NLR, neutrophil-to-lymphocyte ratio; ICI, immune checkpoint inhibitor; Nivo, Nivolumab; Pembro, pembrolizumab; Durva; durvalumab; PD-1, programmed cell death-1; PD-L1, programmed cell death-ligand 1.